Most people with paroxysmal nocturnal hemoglobinuria (PNH) benefited from Soliris (eculizumab) therapy when they adhered to strict treatment guidelines, a real-world Dutch study showed. Because most had an incomplete response, new therapies are needed to improve real-world outcomes, however, the study’s researchers suggested, and emphasized that their data could…
News
Recent Posts
- I’m navigating a new chapter with PNH, one between fear and hope
- Fabhalta more effective than Empaveli for anemia in PNH, data suggest
- Biogen to acquire Apellis, adding PNH treatment Empaveli to portfolio
- Rethinking what control looks like after a PNH diagnosis
- New study backs approved Voydeya dosing for PNH add-on treatment